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SALUTARY EFFECTS OF 
EXOGENOUS ADENOSINE 
ADMINISTRATION ON 
IN VIVO MYOCARDIAL 
STUNNING 
Augmentation ofendogenous adenosine l vels is associated with decreased 
myocardial ischemic-reperfusion njury. The purpose of this study was to 
determine whether exogenous adenosine administered before ischemia 
could attenuate postischemic myocardial dysfunction. Regional myocardial 
stunning was induced by 15 minutes of coronary artery occlusion and 90 
minutes of reperfusion in an open-chest canine preparation. Regional 
ventricular function was assessed by measurement of systolic wall thicken- 
ing. Control untreated hearts were compared with two groups of hearts 
treated immediately before ischemia with intracoronary adenosine (5 gg/kg 
9 per minute and 50 ~g/kg per minute). A fourth group of hearts was treated 
for the first 30 minutes of reperfusion with adenosine (50 /~g/kg per 
minute). Preischemic adenosine administration i creased coronary flow 
sixfold to sevenfold without altering regional function, mean arterial 
pressure, or left ventricular end-diastolic pressure. Both adenosine pre- 
treatments attenuated stunning compared with results in control animals 
(14.7% • 5.1% and 21.6% - 7.3% of preischemic systolic wall thickness 
versus -14.0% • 10%). Adenosine treatment during reperfusion tran- 
siently increased function in parallel with increased coronary blood flow, 
but after termination of the infusion regional function was not different 
from that in control stunned hearts ( -5.0% - 13.1% of preischemic 
systemic wall thickness). These results indicate that adenosine pretreat- 
ment is associated with attenuation of stUnning, an effect that can be 
produced at doses that do not alter systemic hemodynamics. (J TnORAC 
CARDIOVASC SURG 1995;110:63-74) 
Mohinder P. S. Randhawa, Jr., MD, Robert D. Lasley, PhD, and 
Robert M. Mentzer, Jr., MD, Madison, Wis. 
p ostischemic myocardial dysfunction that follows 
a brief ischemic episode insufficient o cause 
irreversible injury is referred to as stunned myocar- 
diumJ This dysfunction can persist for hours to days 
depending on the severity and duration of the 
antecedent ischemic event and occurs despite resto- 
ration of normal coronary blood flow (CBF). There 
is evidence that myocardial stunning is seen clini- 
cally after cardiac surgery and coronary ~hromboly- 
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sis. 2 Although the mechanism or mechanisms re- 
main unknown, 3 much interest has been generated 
to develop therapeutic interventions to prevent or 
minimize myocardial stunning. 
One of the agents currently under investigation is 
the rapidly metabolized purine nucleoside adeno- 
sine. Adenosine has been reported to enhance myo- 
cardial energy status, 4 prolong the time to onset of 
ischemic ontracture, 5 and reduce infarct size. 6 El- 
evation of endogenous adenosine levels with aden- 
osine metabolism inhibitors has been reported to 
reduce postischemic dysfunction. 7-1~ Adenosine has 
also been proposed to mediate the infarct-size- 
reducing effect of ischemic preconditioning. 11 
Adenosine xerts its numerous cardiovascular ef- 
fects by interacting with specific membrane proteins, 
referred to as adenosine A 1 and A z receptors, 
located primarily on cardiac myocytes and endothe- 
lial cells, respectivelyJ 2 The results of studies with 
adenosine A 1 receptor agonists and antagonists 
support the hypothesis that the cardioprotective 
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effect of adenosine is mediated via the interaction of 
adenosine with the A 1 receptor, s'6, 13 The adenosine 
A 1 receptor mechanism is contingent on accumula- 
tion of adenosine in the interstitial fluid (ISF) that 
bathes the cardiac myocytes. There are few if any in 
vivo studies, however, that have directly tested this 
hypothesis, most likely because of the rapid metab- 
olism of adenosine and potential systemic hemody- 
namic side effects. The purpose of  this study was 
therefore to determine (1) whether exogenous aden- 
osine exerts a cardioprotective effect in an in vivo 
regional stunning model and (2) whether timing of 
adenosine administration is critical in altering post- 
ischemic dysfunction. 
Material and methods 
General experimental preparation. All experiments 
were conducted in accordance with the guidelines et by 
the National Institutes of Health in the Guide for the Care 
and Use of Laboratorv Animals (DHEW Publication No. 
85-23) and were approved by the Laboratory Animal Care 
Committee at the University of Wisconsin-Madison. 
Healthy, adult mongrel dogs of either sex weighing 
20 to 25 kg were premedicated with morphine sulfate 
(3 mg/kg intramuscularly) and then anesthetized with 
sodium pentobarbital (30 mg/kg intravenously) with peri- 
odic supplementation (0.5 to 1.0 mg/kg intravenously). 
The  animals were intubated and the lungs ventilated 
(model 613 dog respirator; Harvard Apparatus, S. Natick, 
Mass.) with a mixture of 100% oxygen and air. Tidal 
volume, respiratory rate, and inspired oxygen content 
were adjusted to maintain oxygen tension between 100 
and 200 mm Hg, carbon dioxide tension at 35 to 45 mm 
Hg, and a physiologic pH. Lactated Ringer's olution was 
administered via a left forelimb vein to maintain hydra- 
tion. Core body temperature was monitored with an 
esophageal temperature probe and was maintained at 
38~ with a heating pad. The left femoral artery was 
cannulated to monitor blood pressure and to obtain 
samples for arterial blood gas analysis. 
A left thoracotomy was done in the fifth intercostal 
space and the fifth rib was excised. The pericardium was 
opened and the heart suspended in a pericardial cradle. A 
segment of the left anterior descending (LAD) coronary 
artery was dissected for a length of 2 to 3 cm just distal to 
the first diagonal branch. On the proximal portion of the 
LAD, a modified 24-gauge catheter was inserted for 
intracoronary infusion of phosphate-buffered saline (PBS) 
solution or adenosine. A snare was placed just distal to the 
catheter to allow placement of a bulldog clamp for 
occlusion of the LAD. An ultrasonic flow probe (model 
2R579; Transonic Systems, Inc., Ithaca, N.Y.) for moni- 
toring LAD CBF was placed distal to the snare. A Millar 
micromanometer (model MPC-500; Millar Instruments, 
Inc., Houston, Tex.) for monitoring left ventricular pres- 
sure was inserted through the apex of the heart into the 
left ventricle. This signal was electronically differentiated 
to obtain dP/dt, the first derivative of left ventricular 
pressure. Regional ventricular function, expressed as per- 
cent systolic wall thlckemng, was assessed with pairs of 
piezoelectric crystals connected to a sonomicrometer (T i- 
ton Technology, San Diego, Calif.). The endocardial 
crystals were embedded in the territories perfused by 
the LAD and left circumflex coronary arteries uch that 
the crystals were positioned on the endocardial surface. 
The epicardial crystals were perpendicularly aligned with 
respect o the endocardial crystals, as determined by the 
signal output on an oscilloscope (Gould 60 MHz oscillo- 
scope 3060; Gould. Inc.. Cleveland, Ohio). Adequacy of 
LAD crystal placement was checked with a 40-second 
LAD occlusion during the equilibration period. The left 
circumflex artery crystal served as a control for the 
stability of the preparation during the experiment. 
Cardiac microdialysis. Cardiac microdialysis probes 
were then inserted into the ventricutar muscle of the beds 
perfused by the LAD and left circumflex arteries. The 
technique of cardiac microdialysis has been described in 
detail. TM In brief, the microdialysis probes, which have a 
2 cm dialysis window and an in vitro recovery rate of 70%, 
were perfused at 2 /xl/min with Krebs-Henseleit buffer 
contained in gas-tight glass syringes. The Krebs-Henseleit 
buffer equilibrates with the myocardial ISF by diffusion as 
it passes through the dialysis fiber. The effluent or dialy- 
sate obtained by this process provides an index of myo- 
cardial ISF nucleoside concentration. The samples were 
collected and stored at 80~ until later analysis by 
high-performance liquid chromatography. Adenosine, in- 
osine, and hypoxanthine were separated with a reverse- 
phase column (Supelcosil C-18; Supelco, Bellefonte, Pa.) 
by previously described methods, '14 Peaks were identi- 
fied and quantitated by comparison of retention times and 
peak areas with external standards by use of a Maxima 
software package (Waters Associates, Marlborough, 
Mass.). 
Canine experimental protocols. Protocols began after a 
90-minute quilibration timed from the insertion of the 
dialysis probes. A previous study demonstrated that 90 
minutes was required for interstitial nucleoside levels to 
return to baseline after insertion of the dialysis probesJ 4
Figure 1 depicts the specific protocols used in the canine 
studies. All groups underwent 40 minutes of preischemia, 
15 minutes of LAD occlusion, and 90 minutes of reperfu- 
sion, except he adenosine postischemic treatment group, 
which underwent reperfusion for 60 minutes. Group 1 
control hearts (n = 12) received PBS in the LAD catheter 
in the preischemic and reperfusion periods. To determine 
the acute effects of adenosine-induced hyperemia in 
stunned myocardium, dogs received a 10-minute infusion 
of adenosine (50 /xg/kg per minute by intracoronary 
administration) at 30 and 60 minutes of reperfusion. 
Groups 2 (n - 9) and 3 (n - 15) received intracoronary 
adenosine infusions for 20 minutes immediately before 
ischemia t doses of 5/xg/kg per minute and 50 ~g/kg per 
minute, respectively.,The length of the adenosine infusion 
was based on the time required to collect two 10-minute 
dialysate fluid collections. Similar to the protocol in group 
1, the effects of brief adenosine infusions were tested 
during reperfusion. Group 4 animals (n - 7) were treated 
with adenosine (50 /zg/kg per minute by intracoronary 
administration) for the initial 30 minutes of reperfusion. 
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Fig. 1. Schematic representation of canine protocols. Group 1, control; group 2, low-dose adenosine 
(ADO, 5." ~g/kg per minute); group 3, high-dose adenosine (50 /xg/kg per minute); and group 4, 
postischemic adenosine treatment (50 tzg/kg per minute). 
The infusion was initiated uring the last minute of 
ischemia. 
Hemodynamic, functional, and interstitial data were 
obtained at 10-minute intervals, except during ischemia 
when data were collected every 5 minutes. Arterial blood 
pressure, heart rate, left ventricular pressure, left ventric- 
ular dP/dt, LAD and left circumfex artery wall thickening, 
CBF, and electrocardiogram were recorded at regular 
intervals on an 8-channel Gould chart recorder (RS 3800, 
Gould, Inc.). Animals were killed with concentrated po- 
tassium chloride at the end of each experiment while 
under deep pentobarbital nesthesia. The ischemic beds 
were stained with an infusion of india ink into the LAD at 
the occlusion site before excision of the heart. The 
ischemic beds were weighed, and the position and orien- 
tation of the sonomicrometric crystals were verified as 
were the locations of the microdialysis probes. 
An average of three consecutive heartbeats was used to 
calculate hemodynamic and functional data. For the cal- 
culation of systolic wall thickening, end diastole was 
defined as the onset of peak positive dP/dt and endsystole 
as 20 msec before peak negative dP/dt. Percent systolic 
wall thickness (% SWT) was calculated by the following 
formula: % SWT = (ESWT - EDWT)/EDWT X 100%, 
where ESWT and EDWT are defined as end:systolic wall 
thickness and end-diastolic wall thickness, respectively. 
Porcine experimental protocols. Similar regional stun- 
ning experiments were done in a small set of pigs (n = 4 
per group) to determine whether the effects of adenosine 
in the ischemic heart were dependent on the presence of 
preexisting collaterals. It is thought hat the porcine heart 
is similar to human myocardium with respect o its low 
native coronary collateral flow. is Durok-Landrace pigs 
(29 to 34 kg) were premedicated with ketamine (1 gm 
intramuscularly) and then anesthetized with sodium pen- 
tobarbital (25 mg/kg intravenously) with maintenance by a 
pentobarbital drip (10 to 15 mg/kg per hour). A trache- 
ostomy was done for airway control followed by anterior 
chest wall removal. The subsequent instrumentation was 
identical to that used in the canine model including 
placement of piezoelectric rystals and cardiac microdi- 
alysis probes. All pigs underwent 20 minutes of preisch- 
emia, 10 minutes of regional LAD occlusion, and 90 
minutes of reperfusion. Reduction of the occlusion time 
from 15 to 10 minutes was necessary to avoid a high 
fibrillation rate and avoid any irreversible ischemic injury. 
Control pigs were treated with PBS infused into the LAD 
catheter during preischemia and reperfusion. The pigs 
were administered lidocaine (2.5 mg/kg intravenously) 30 
seconds before reperfusion. Animals pretreated with 
adenosine were administered intracoronary adenosine 
(100/zg/kg per minute) for 10 minutes immediately before 
ischemia. 
Materials. Adenosine was purchased from Sigma 
Chemical (St. Louis, Mo.). A stockisolution of 2.5 mg/ml 
of adenosine was made in PBS and was infused at 0.45 to 
0.52 ml/min. All chromatography reagents were high- 
performance liquid chromatography grade. 
Statistical analysis. All data are expressed as means 
plus or minus the standard error of the mean. Functional, 
hemodynamic, and metabolic differences within groups 
were determined with either one-way repeated-measures 
analysis of variance or analysis of covariance. If a signifi- 
cant F ratio was obtained, further comparisons were 
determined with Newman-Keuls post-hoc test. Differ- 
ences between groups were ascertained with orthogonal 
planned comparisons among the groups, and F ratios with 
p < 0.05 were considered significant. 
Results 
Canine preparation. Of  the 75 dogs entered into 
the study 32 were excluded from final data analysis. 
Exclusion was based on the following criteria: (1) 
absence of dyskinesis during LAD occlusion, (2) 
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Table I. Summary of dogs entered into protocols 
Absence of No. completed 
Group* No. in study dyskinesis Fibrillation Heartworms study 
1 25 1 7 5 12 
2 16 2 5 - -  9 
3 23 3 5 - -  15 
4 11 3 1 - -  7 
Total 7--5 9 1-8 f f  4-3 
*Group 1, control; group 2, pretreatment with low-dose adenosine; group 3, pretreatment with high-dose adenosine; group 4, postischemic adenosine 
treatment. 
Table II. Hemodynamic variables in canine groups 
Reperfusion 
Group Baseline Preischemia Ischemia 30 min 60 min 90 min 
MAP (mm Hg) 1 100 • 5.3 102 4- 4.7 97 4- 4.1 97 4- 4.3 93 4- 4.5* 93 4- 4.2* 
2 99 4- 5.0 98 --- 4.4 95 --- 3.9 94 _+ 4.2 88 4- 3.4* 88 4- 3.3* 
3 99 4- 3.1 95 _+ 3.5# 96 4- 3.2 99 4- 2.6 97 --- 2.7~: 96 --- 2.3:~ 
4 104 4- 7,1 101 4- 6.5 103 + 6.7 98 4- 6.4 100 -+ 6.0:~ - -  
HR (beats/min) 1 114 4- 7.7 115 -+ 7.8 125 4- 6.9* 129 4- 6.4* 131 4- 6.9* 134 _+ 6.7* 
2 123 + 6.0 130 4- 4.5* 135 4- 4.4* 136 + 4.6* 139 - 4.4* 143 4- 5.4* 
3 131 4- '4.9 148 4- 3.6*w 139 4- 4.7 137 _+ 5.3 144 4- 5.4* 146 4- 6.2* 
4 117 4- 9.8 122 4- 9.4 132 4- 9.5* 140 4- 8.9* 137 --- 7.7* - -  
dP/dt (mm Hg/sec) 1 1865 + 83 1887 4- 77 1719 -4- 70* 1693 4- 65* 1674 4- 63* 1674 + 72* 
2 1576 4- 94? 1603 _+ 88 1476 + 74* 1462 4- 74* 1432 4- 66* 1415 4- 69* 
3 1979 4- 67 2364 + 111"w 1824 _+ 67~ i895 4- 60 1932 4- 78w 1892 _+ 82 
4 1805 -+ 101 1737 _+ 107 1719 _+ 102 1748 • 114 1601 -+ 100" - -  
LVEDP (mm Hg) 1 6.9 • 0.9 6.8 • 1.0 8 .5  • 0.7 7.3 • 0.8 7.8 • 1.1 7.3 • 1.0 
2 6.7 -- 0.7 7.1 • 0.9 7.9 _+ 1.0 6.9 _+ 1.1 6.7 4- 1.2 6.9 • 1.4 
3 6.1 • 0.8 5.6 • 0.9 6.5 • 0.8 6,3 4- 0.8 6.3 -+ 1.0 5.9 -+ 0.9 
4 5.9 -+ 1.8 6.0 • 1.8 8.0 • 2.0 7.3 • 1.5 6.7 • 1.4 - -  
Values are mean plus or minus standard error of mean. MAP, Mean arterial pressure; HR, heart rate; LVEDP, 
*p < 0.05 versus baseline, 
tp < 0.01 versus group 1. 
< 0.01 versus group 2. 
w < 0.05 versus groups 1, 2, and 4. 
left ventricular end-diastolic pressure. 
ventrieular fibrillation during ischemia or reperfu- 
sion, and (3) the presence of heartworms, which was 
assessed at the conclusion of each experiment (Ta- 
ble I). A ~ analysis did not demonstrate any 
differences in the rate of fibrillation among the 
groups. The remaining 43 animals were included in 
all hemodynamic and functional data assessments. 
The ischemic bed sizes were expressed as a percent 
of the left ventricle. There were no significant 
differences in the size of the ischemic beds among 
the groups (35.0% --- 1.7%, 30.2% _ 2.6%, 33.8% • 
2.0%, and 30.7% --- 1.4% for groups 1 through 4, 
respectively). The effects of the various treatments 
on hemodynamic parameters are presented inTable 
II. Baseline mean arterial pressure, heart rate, and 
left ventricular end-diastolic pressure were similar 
among the groups, with the exception of +dP/dt, 
which was lower in the pretreatment low-dose 
group. Preischemic nfusion of adenosine increased 
heart rate at the 5 tzg/kg per minute dose and 
increased both heart rate and +dP/dt at 50 ~g/kg 
per minute. During ischemia there were no inter- 
group differences in mean arterial pressure, heart 
rate, or left ventricular end-diastolic pressure. The 
only significant difference in systemic hemodynamic 
parameters among the groups during reperfusion 
was better preservation of baseline mean arterial 
pressure and +dP/dt in the animals pretreated with 
high-dose adenosine. 
There were no differences between the groups in 
the metabolism and function of the nonstunned left 
circumflex artery region throughout the experiment. 
Dialysate adenosine concentrations in the bed per- 
fused by the left circumflex coronary .artery were 
similar at baseline (0.46 _+ 0.07, 0.41 + 0.10, 0.47 + 
0.09, and 0.41 _+ 0.07/zmol/L for groups 1 through 4, 
The Journal of Thoracic and 
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Fig. 2. Effects of adenosine (ADO) treatments on dlalysate adenosine l vels during preischemia (PRE-I), 
ischemia (ISC), and reperfusion (RP) in canine xperiments. *p < 0.05 versus preinfusion levels; ?p < 0.01 
versus groups 1, 2, and 4. Values are expressed as mean plus or minus tandard error of mean, 
respectively) and remained stable for the duration 
of the experiment. Baseline systolic function of the 
left circumflex artery region, expressed as percent 
systolic wall thickness, was similar in all groups 
(18.5% + 1.5%, 17.7% _ 1.7%, 17.4% _+ 1.5%, and 
15.4% +_ 2.5% for groups i through 4, respectively). 
After 90 minutes of reperfusion onischemic left 
circumflex artery regional function expressed as 
percent of preischemic values was 93% _+ 6.1%, 
102% +_ 5.4%, 83% _+ 6.2%, and 98% _ 13.2% for 
groups 1 through 4, respectively. 
Dialysate adenosine l vels were similar among the 
groups at baseline (Fig. 2). Pretreatment with 5 
/xg/kg per minute adenosine had no effect on dialy- 
sate adenosine values compared with control values. 
In contrast, dialysate adenosine concentration dou- 
bled during adenosine infusion at 50 /xg/kg per 
minute (0.55 + 0.12/xmol/L to 1.25 _+ 0.30/xmol/L, 
p < 0.05). The majority of the nucleosides in this 
group were in the form of the adenosine metabolites 
inosine, which increased eightfold, and hypoxan- 
thine, which increased fourfold. During regional 
ischemia there was a comparable fivefold to sixfold 
increase in dialysate adenosine l vels in all groups. 
ISF adenosine was rapidly washed out during reper- 
fusion, such that by 20 minutes of reperfusion, 
adenosine l vels returned to preischemic values in 
control and both pretreated groups. The brief aden- 
osine infusions (50/xg/kg per minute) at 30 minutes 
of reperfusion i  control animals and animals pre- 
treated with adenosine increased ialysate adeno- 
sine concentration (0.39 +__ 0.07 /xmol/L to 1.38 _+ 
0.52/xmol/L and 0.41 + 0.09/~mol/L to 0.99 + 0.20 
ixmol/L, respectively, p < 0.05). Dialysate adenosine 
levels rapidly returned to preinfusion values with 
cessation of the adenosine infusion. A similar re- 
sponse was seen during a second adenosine infusion 
at 60 minutes of reperfusion. 
In the postischemic treatment group (group 4), 
adenosine infusion during the initial 30 minutes of 
reperfusion did not increase dialysate adenosine 
levels compared with those in the other groups. The 
levels of adenosine metabolites inosine and hypo- 
xanthine also were not altered during the initial 10 
minutes of reperfusion, but were elevated at 20 and 
30 minutes of reperfusion compared with those of 
control and both pretreatment groups (p < 0.05). 
The effects of the various treatments on myocar- 
dial stunning are illustrated in Fig. 3. The LAD 
percent systolic wall thickening was similar at base- 
line (16.6% + 1.6%, 19.2% + 1.6%, 16.7% + 1.3%, 
and 17.5% + 1,9% for groups 1 through 4, respec- 
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Fig. 3. Time course of changes in regional ventricular function, expressed as percent of baseline systolic 
wall thickening (SWT), in the LAD-perfused bed. ADO, Adenosine; PRE-I, preischemia; ISC, ischemia; 
RP, reperfusion. *p < 0.01 versus group 1; #p < 0.01 versus preinfusion values. 
tively). During preischemic adenosine infusion there 
was no change in regional function from baseline 
(19.2% _+ 1.6% versus 19.8% _+ 1.7% and 16.7% + 
1.3% versus 17.6% + 1.6% for the low- and high- 
dose adenosine groups, respectively). All groups 
demonstrated comparable l vels of systolic thinning 
during LAD occlusion. After 10 minutes of reper- 
fusion both adenosine pretreatment groups exhib- 
ited elevated systolic wall thickening (21.6% _+ 7.3% 
and 19.0% _ 10.9% of preischemic Values, respec- 
tively), whereas control hearts exhibited systolic 
thinning. After 90 minutes of reperfusion regional 
function in the low-dose group was 14.7% _+ 5.1%, 
whereas in the pretreated high-dose group it was 
26.2% + 10.0%. Adenosine infusion during the 
initial 30 minutes of reperfusion was associated with 
a slight, but not significant, increase in regional 
function. However, on termination of the adenosine 
infusion, function rapidly decreased from 3.6% _+ 
17.4% to -11.1% _+ 13.2% of baseline. At 60 
minutes of reperfusion, LAD regional function was 
-5.0% + 13.1% in this group, comparable to that in 
control animals (-14.0% _ 10.0% at 60 minutes of 
reperfusion) (Fig. 3). 
Levels of CBF were similar in all groups at the 
onset of the experimental protocols (18 _+ 2 ml/min, 
21 _+ 2 ml/min, 17 _+ 2 ml/min, and 15 _+ 2 ml/min in 
groups 1 through 4, respectively) and at the conclu- 
sion of the experiment. As shown in Fig. 4, preisch- 
emic adenosine infusion (5 and 50 /xg/kg per 
minute) increased CBF sixfold to sevenfold but had 
no effect on regional systoli c function. In contrast, 
during adenosine infusions at 30 and 60 minutes of 
reperfusion in control and both pretreatment 
groups, a similar increase in CBF was associated 
with increased regional function that lasted for the 
duration of the adenosine infusions (p < 0.05 within 
each group, Fig. 3). Function rapidly returned to 
levels before adenosine administration with cessa- 
tion of the adenosine infusions, 
Porcine studies. Of the eight animals studied, 
none was excluded from final data analysis. There 
was no significant difference in ischemic bed size, 
expressed as a percent of the left ventricle, between 
the groups (39.05% _+ 0.39% versus 35.37% _+ 
2.88% in control and adenosine-pretreated groups, 
respectively). There were no differences in any 
hemodynamic parameters between the groups, and 
the administration of adenosine had no systemic 
hemodynamic effects. Levels of CBF were similar in 
control and adenosine-pretreated groups at baseline 
(22 _+ 3 ml/min versus 22 _ 3 ml/min, respectively) 
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Fig. 4. Relationship between regional ventricular function and CBF in normal and stunned myocardium. 
A, Effects of intracoronary adenosine (ADO, 5 and 50 txg/kg per minute) on LAD CBF before and after 
stunning (groups 2 and 3). *p < 0.01 versus before adenosine infusion. B, Effects of adenosine (ADO) on 
LAD systolic wall thickening (SWT) in normal and stunned myocardium. *p < 0.01 versus before 
adenosine infusion. 
and were comparable at the end of the experiments 
(19 • 3 ml/min versus 18 _+ 3 ml/min, respectively). 
The preischemic adenosine infusion increased CBF 
sevenfold, but had no effect on regional LAD func- 
tion. 
The alterations in dialysate adenosine levels are 
illustrated in Fig. 5. Dialysat e adenosine levels were 
similar between the groups at baseline (0.64 +_ 0.15 
#xmol/L and 0.79 _+ 0.03 /xmol/L for control and 
adenosine-pretreated groups, respectively). Intra- 
coronary adenosine infusion (100 txg/kg per minute) 
significantly increased dialysate adenosine levels 
ninefold in the pretreatment group (6.98 -- 2.45 
/xmol/L,p < 0.001), but, similar to results in the dog, 
the majority of the nucleosides were in the form of 
adenosine metabolites inosine and hypoxanthine. 
There were no further differences in dialysate aden- 
osine levels during ischemia or reperfusion. 
7 0 Randhawa, Lasley, Mentzer 
The Journal of Thoracic and 
Cardiovascular Surgery 
July 1995 
25 
20 
Dialysate 15 
[ADO] 
(gU) 10 
O- -  Control 
mic 
ADO 
I I qr 
f 
10 20 
PRE-I ~ ~ 10 RP 
ISC(~ 10 2(1 30 4() 50 6() 70 86 9s 
Time (min) 
01 , 
0 
Fig. 5. Time course of changes indialysate adenosine (ADO) levels during preischemia (PRE-I), ischemia 
(ISC), and reperfusion (RP) in control and adenosine-pretreated (100p~g/kg per minute) pigs. *p < 0.001 
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The effects of adenosine on regional myocardial 
function are illustrated in Fig. 6. The baseline 
regional LAD percent systolic wall thickening was 
similar in control and adenosine-pretreated groups 
(26.8% + 2.5% and 29.3% _+ 4.2%, respectively). 
Regional LAD function did not change significantly 
during the preischemic adenosine infusion and both 
groups demonstrated comparable dyskinesis during 
LAD occlusion. There was no difference in regional 
function during reactive hyperemia, but for the 
remainder of reperfusion the adenosine pretreat- 
ment group demonstrated significantly greater func- 
tional recovery (35.1% _+ 4.5% versus 19.1% + 
6.0% of baseline values). 
Discuss ion  
Intracoronary infusion of adenosine immediately 
before ischemia was associated with elevated ISF 
adenosine levels, minimal systemic hemodynamic 
effects, and a sustained attenuation of myocardial 
stunning in canine and porcine hearts. In contrast, 
administration of adenosine for 30 minutes at the 
onset of reperfusion only marginally increased re- 
giona! Ventricular function, an effect that rapidly 
dissipated on termination of the adenosine infusion 
in parallel with a return of CBF to basal levels. 
These findings are consistent with the hypothesis 
that adenosine is a cardioprotective agent in vivo 
and suggest hat the optimum time for adenosine 
administration is before the onset of ischemia. 
There is substantial evidence that adenosine x- 
erts beneficial effects in both reversibly and irrevers- 
ibly injured myocardium, s' 6, 13 The majority of in 
vivo studies have been done with adenosine metab- 
olism inhibitors and slowly metabolized adenosine 
receptor analogs. Elevation of endogenous adeno- 
sine level with nucleoside transport 9' 10 or adenosine 
deaminase inhibitors 7-9 has been shown to decrease 
in vivo postischemic ventricular dysfunction. In 
these studies adenosine l vels were either not mea- 
sured 7, 10 or total tissue levels were assessed. 9 Tissue 
adenosine measurements comprise intracellular, in- 
terstitial, and vascular compartments and thus pro- 
vide little information on adenosine levels in the 
compartments in contact with adenosine A1 and A2 
receptors (that is, interstitial and vascular compart- 
ments, respectively). Dorheim et al., s using the same 
microdialysis technique as used in this study, re- 
ported that treatment before ischemia with the 
adenosine deaminase inhibitor 9-erythro-2-(hy- 
droxy-3-nonyl) adenine (EHNA) increased ISF 
adenosine levels and postischemic recovery of re- 
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gional ventricular function. Because myocyte aden- 
osine A 1 receptors are in contact with ISF, these 
results supported the hypothesis that adenosine 
attenuates myocardial stunning by an A 1 receptor 
hypothesis. 
There are few, if any, in vivo studies; however, on 
the effects of exogenous adenosine on reversible 
postischemic function. This is 'most likely because 
adenosine is rapidly metabolized by vascular endo- 
thelial and red blood cells 16 and consequently high 
doses of adenosine must be delivered to achieve 
adequate myocardial levels. IntracoronarY adeno- 
sine at a dose (5 /xg/kg per minute) that produced 
maximal coronary vasodilation did not increase ISF 
adenosine levels as determined by microdialysis. A 
10-fold greater infusion rate increased ISF adeno- 
sine levels only twofold (from 0.6 + 0.1 /xmol/L to 
1.2 _+ 0.3/xmol/L), whereas the metabolites inosine 
and hypoxanthine increased eightfold and fourfold, 
respectively. Increasing the adenosine infusion rate 
to 100 /xg/kg per minute in the pig increased ISF 
adenosine levels ninefold. Although plasma adeno- 
sine levels were not measured in this study, we have 
measured coronary venous plasma levels during a 50 
/xg/kg per minute intracoronary adenosine infusion 
in the pig. This dose increased ISF adenosine levels 
similar to the increase in the dog (from 0.5 2 0.05 
/xmol/L to 2.0 _+ 0.1 /xmol/L), but the plasma 
adenosine level increased 50-fold (from 0.3 + 0.09 
/xmol/L to 15.2 _+ 1.8/xmol/L, unpublished observa- 
tions). These results provide in vivo evidence of the 
metabolic barrier to exogenous adenosine as has 
been reported in vitro. 16 
The infusion of 5/xg/kg per minute adenosine in 
the dog produced no detectable change in dialysate 
adenosine concentration but was associated with 
enhanced postischemic function. Although plasma 
adenosine levels were undoubtedly increased, it is 
possible that adenosine was completely metabolized 
before reaching the interstitial space. This would 
suggest that adenosine need not accumulate in the 
ISF to exert its protective ffect. Although this may 
in fact be the case there are several alternative 
explanations. If the adenosine was completely me- 
tabolized by endothelial cells, we would have ex- 
pected to see increased inosine and hypoxanthine 
levels, which was not the case. The inability to detect 
any increase in dialysate adenosine levels with this 
treatment may also be a result Of the adenosine- 
induced hyperemia. Although the dialysis technique 
has several advantages, it provides only an estimate 
of interstitial metabolites and is influenced by 
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changes in blood flow. 17' 18 Increased CBF results in 
increased washout and an increase in the volume of 
the interstitial space. It is also possible that the 
resulting increase in myocardial oxygen supply may 
have actually decreased adenosine production. 17
Most likely, the higher dose of adenosine produced 
a sufficient plasma concentration to overcome the 
effects of rapid metabolism and increased interstitial 
washout. 
Although there has been much concern expressed 
over the potential hemodynamic effects of the ad- 
ministration of adenosine, the three dosages used in 
this study were associated with few systemic hemo- 
dynamic effects. The lower adenosine dosage (5 
/zg/kg per minute) in the dog and the higher dosage 
(100 t~g/kg per minute) in the pig had no systemic 
effects. The 50 tzg/kg per minute adenosine infusion 
in the dog was associated with a small drop in 
arterial pressure and significant increases in heart 
rate and left ventricular +dP/dt, most likely because 
of baroreceptor reflex mechanisms or the activation 
of sympathetic afferents as has been suggested to 
occur in conscious human beings. 19'2~ Although 
these effects are suggestive of increased myocardial 
oxygen demand at the onset of ischemia, this group 
exhibited the greatest attenuation of myocardial 
stunning in the caninestudy. It is evident from these 
results that the cardioprotective effect of adenosine 
was independent of and not compromised by its 
hemodynamic effects. 
Although the mechanism of adenosine-mediated 
cardioprotection was not directly addressed in this 
study, the  results do provide some insight into 
potential mechanisms. The observation that ade- 
nosine-enhanced postischemic function was associ- 
ated with elevated preischemic ISF adenosine l vels 
is consistent with the adenosine A 1 receptor hypoth- 
esis because the concentration f aden'osine in the 
interstitial space determines the amount of adeno- 
sine in the vicinity of the A 1 receptor. The role of A1 
receptors in the beneficial effect of adenosine is 
based on studies with adenosine receptor agonists 
and antagonists. 5' 6, la, 13 However, this is the first 
study that documents an association between exog- 
enous adenosine-mediated increases in ISF adeno- 
sine levels and an attenuation of myocardial stun- 
ning. 
It is possible that the beneficial effects of adeno- 
sine could have been secondary to  enhanced 
collateral blood flow during ischemia, which 
would have limited the degree of injury and 
/ 
facilitated functional recovery. It is well known 
that collateral blood flow is an important deter- 
minant of ischemic injury, especially in dogs. 21 
Because collateral blood flow was not measured 
this potential mechanism cannot be excluded. 
However, the adenosine infusion was terminated 
at the onset of ischemia and there were no 
differences in dialysate adenosine levels during 
ischemia mong the groups. With the rapid me- 
tabolism of adenosine it is unlikely that adenosine 
infused into the LAD accumulated in the systemic 
circulation at levels great enough to promote 
coronary collateral vasodilation. Furthermore, the 
results from the porcine model, which has been 
shown to have very little native collateral blood 
flow, 15 indicate that the cardioprotective effect of 
adenosine is independent of collateral blood flow. 
The inability to detect an increase in dialysate 
adenosine levels during the 5 /xg/kg per minute 
adenosine infusion does not preclude the interac- 
tion of adenosine with the A1 receptor, but it is 
possible that the lower adenosine dosage protected 
the heart independent of adenosine A1 receptor 
activation. Adenosine increased CBF sixfold to sev- 
enfold, which indicates activation of adenosine A e 
receptors. However, the results of numerous studies 
with adenosine receptor agonists uggest hat the 
adenosine Ae receptor plays little role in protecting 
the ischemic heart. 5'6' 11, 13 Early studies on the 
protective effect of adenosine were based on the role 
of adenosine as an adenine nucleotide precursor, 
but there is now substantial evidence that ade- 
nosine-mediated cardioprotection a3, ee and postisch- 
emic recovery of function e3 are not dependent on 
tissue adenosine triphosphate l vels. 
There are several reports that treatment with 
adenosine transport/metabolism nhibitors attenu- 
ates myocardial stunning. 7-1~ It is not clear from 
these studies what the exact mechanism of cardio- 
protection is, but we have reported that adenosine 
deaminase inhibition and adenosine transport 
blockade both increase ISF adenosine levels. 1~ 24 
These results are thus consistent with an adenosine 
A 1 receptor mechanism. It has also been proposed 
that by preventing adenosine metabolism, these 
agents decrease the substrates (hypoxanthine and 
xanthine) for xanthine oxidase-induced oxygen free 
radical production. 9 Although this may be a poten- 
tial mechanism, the 50/xg/kg per minute adenosine 
infusion in the dogs, which increased hypoxanthine 
levels fourfold, appeared to exert no detrimental 
effects. In addition, adenosine treatment in the pig 
heart, which similar to human myocardium has little 
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xanthine oxidase activity, 25 was also cardioprotec- 
tive. 
The observation that adenosine treatment during 
the early reperfusion period failed to attenuate 
stunning indicates that adenosine must be adminis- 
tered (that is, the adenosine A 1 receptor activated) 
before the onset of or during ischemia to attenuate 
postischemic ventricular dysfunction. These results 
suggest hat adenosine xerts its protective ffect 
during the ischemic period. Adenosine infusion 
transiently increased regional function in the 
stunned heart, but not in the normal heart. This 
effect, which has been reported by others, 26-2s is 
most likely an indirect effect because adenosine has 
no direct inotropic effects in mammalian ventricular 
myocardium. 12The apparent positive inotropic ef- 
fect of adenosine in the stunned heart appears to be 
related to increased CBF, inasmuch as it dissipated 
with the same time course as adenosine-induced 
hyperemia when the infusion was terminated. This 
effect may be related to the hyperemia-induced 
increase in wall thickness 29 or caused by an increase 
in oxygen delivery. 
Adenosine has received much interest recently in 
its role in the infarct-size-reducing effect ofischemic 
preconditioning, al Although adenosine reduces 
both reversible and irreversible myocardial ischemic 
injury, the mechanisms by which it does so remain 
unclear. Neither ischemic preconditioning 3~31 nor a 
transient infusion of adenosine followed by washout 
attenuates myocardial stunning. 32-34 It thus appears 
that myocardial adenOsine levels must be elevated 
and adenosine A 1 receptors activated at the time of 
onset of ischemia to enhance postischemic function. 
For these reasons we refer to our treatment as 
"adenosine pretreatment" not "adenosine precon- 
ditioning." 
Adenosine has been used clinically for the .treat- 
ment of Supraventricular rrhythmias, 35 coronary 
perfusion imaging, 36 and postoperative hyperten- 
sion, 37 but because of its rapid metabolism and 
systemic effects these intravenous adenosine regi- 
mens may not be pr~actical for protecting the isch- 
emic heart. The results of this study, and of human 
studies, 19'2~ however, suggest that intracoronary 
adenosine is well tolerated and may be cardiopro- 
tective in certain clinical settings, such as heart 
surgery and angioplasty. 
We gratefully acknowledge the technical assistance of 
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